COARTEM Drug Patent Profile
✉ Email this page to a colleague
When do Coartem patents expire, and what generic alternatives are available?
Coartem is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in COARTEM is artemether; lumefantrine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the artemether; lumefantrine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COARTEM?
- What are the global sales for COARTEM?
- What is Average Wholesale Price for COARTEM?
Summary for COARTEM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| Clinical Trials: | 91 |
| Drug Prices: | Drug price information for COARTEM |
| What excipients (inactive ingredients) are in COARTEM? | COARTEM excipients list |
| DailyMed Link: | COARTEM at DailyMed |
Recent Clinical Trials for COARTEM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 3 |
| MMV, EDCTP, WANECAM | Phase 3 |
| Global Fund | Phase 4 |
Pharmacology for COARTEM
| Drug Class | Antimalarial |
US Patents and Regulatory Information for COARTEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | COARTEM | artemether; lumefantrine | TABLET;ORAL | 022268-001 | Apr 7, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COARTEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | COARTEM | artemether; lumefantrine | TABLET;ORAL | 022268-001 | Apr 7, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COARTEM
See the table below for patents covering COARTEM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 238477 | ANTI-MALARIAL COMPOSITION COMPRISING BENFLUMETOL AND AT LEAST ONE OF ARTEMISININE, ARTEMETHER, ARTEETHER, DIHYDROARTEMISININE AND ARTESUNATE | ⤷ Sign Up |
| Hungary | 9201528 | ⤷ Sign Up | |
| South Africa | 9104490 | ⤷ Sign Up | |
| Germany | 69117922 | ⤷ Sign Up | |
| European Patent Office | 0500823 | COMPOSITIONS ANTIPALUDEENNES (ANTIMALARIAL COMPOSITIONS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COARTEM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0500823 | SPC/GB00/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ARTEMETHER AND LUMEFANTRIN; REGISTERED: CH (IKS) 54594 01 19990122; UK PL 00101/0566 19991130 |
| 0500823 | 2001C/043 | Belgium | ⤷ Sign Up | PRODUCT NAME: ARTEMETHER, LUMEFANTRINE; NAT. REGISTRATION NO/DATE: 206 IS 300 F 3 20010514; FIRST REGISTRATION: CH 54594 19990122 |
| 0500823 | C300048 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ARTEMETHERUM EN LUMEFANTRINUM, DESGEWENST IN DE VORM VAN EEN FA RMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ARTEMETHERUM EN LUMEFANTRINUM; NATL. REGISTRATION NO/DATE: RVG 25773 20010123; FIRST REGISTRATION: CH 54594 19990122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
